Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jan 12;1(1):CD001415.
doi: 10.1002/14651858.CD001415.pub4.

Gabapentin add-on treatment for drug-resistant focal epilepsy

Mariangela Panebianco  1 , Sarah Al-Bachari  2 , Jane L Hutton  3 , Anthony G Marson  1   4   5
Affiliations
Meta-Analysis

Gabapentin add-on treatment for drug-resistant focal epilepsy

Mariangela Panebianco et al. Cochrane Database Syst Rev. .

Abstract

Background: This is an updated version of the Cochrane Review previously published in 2018. Epilepsy is a common neurological disorder characterised by recurrent seizures. Most people with epilepsy have a good prognosis and their seizures are well controlled by a single antiepileptic drug, but up to 30% develop drug-resistant epilepsy, especially people with focal seizures. In this review, we summarised the evidence from randomised controlled trials (RCTs) of gabapentin, when used as an add-on treatment for drug-resistant focal epilepsy.

Objectives: To evaluate the efficacy and tolerability of gabapentin when used as an add-on treatment for people with drug-resistant focal epilepsy.

Search methods: For the latest update, we searched the Cochrane Register of Studies (CRS Web) and MEDLINE (Ovid) on 11 August 2020. CRS Web includes randomised or quasi-randomised, controlled trials from PubMed, Embase, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform (ICTRP), the Cochrane Central Register of Controlled Trials (CENTRAL), and the Specialised Registers of Cochrane Review Groups including Epilepsy. We imposed no language restrictions.

Selection criteria: Randomised, placebo-controlled, double-blind, add-on trials of gabapentin in people with drug-resistant focal epilepsy. We also included trials using an active drug control group or comparing different doses of gabapentin.

Data collection and analysis: Two review authors independently selected trials for inclusion and extracted the relevant data. We assessed the following outcomes: seizure frequency, seizure freedom, treatment withdrawal (any reason) and adverse effects. Primary analyses were intention-to-treat. We also undertook sensitivity best-case and worst-case analyses. We estimated summary risk ratios (RR) for each outcome and evaluated dose-response in regression models.

Main results: We identified no new studies for this update, therefore, the results and conclusions are unchanged. In the previous update of this review, we combined data from six trials in meta-analyses of 1206 randomised participants. The overall risk ratio (RR) for reduction in seizure frequency of 50% or more compared to placebo was 1.89 (95% confidence interval (CI) 1.40 to 2.55; 6 studies, 1206 participants; moderate-certainty evidence). Dose regression analysis (for trials in adults) showed increasing efficacy with increasing dose, with 25.3% (95% CI 19.3 to 32.3) of people responding to gabapentin 1800 mg compared to 9.7% on placebo, a 15.5% increase in response rate (95% CI 8.5 to 22.5). The RR for treatment withdrawal compared to placebo was 1.05 (95% CI 0.74 to 1.49; 6 trials, 1206 participants; moderate-certainty evidence). Adverse effects were significantly associated with gabapentin compared to placebo. RRs were as follows: ataxia 2.01 (99% CI 0.98 to 4.11; 3 studies, 787 participants; low-certainty evidence), dizziness 2.43 (99% CI 1.44 to 4.12; 6 studies, 1206 participants; moderate-certainty evidence), fatigue 1.95 (99% CI 0.99 to 3.82; 5 studies, 1161 participants; low-certainty evidence) and somnolence 1.93 (99% CI 1.22 to 3.06; 6 studies, 1206 participants; moderate-certainty evidence). There was no evidence of a difference for the adverse effects of headache (RR 0.79, 99% CI 0.46 to 1.35; 6 studies, 1206 participants; moderate-certainty evidence) or nausea (RR 0.95, 99% CI 0.52 to 1.73; 4 trials, 1034 participants; moderate-certainty evidence). Overall, the studies were at low to unclear risk of bias due to information on each risk of bias domain not being available. We judged the overall certainty of the evidence (using the GRADE approach) as low to moderate due to potential attrition bias resulting from missing outcome data and imprecise results with wide CIs.

Authors' conclusions: Gabapentin has efficacy as an add-on treatment in people with drug-resistant focal epilepsy, and seems to be fairly well-tolerated. However, the trials reviewed were of relatively short duration and provide no evidence for the long-term efficacy of gabapentin beyond a three-month period. The results cannot be extrapolated to monotherapy or to people with other epilepsy types. Further trials are needed to assess the long-term effects of gabapentin, and to compare gabapentin with other add-on drugs.

PubMed Disclaimer

Conflict of interest statement

MP: none known. SAB: none known. JLH: none known. AGM is part funded by the National Institute for Health Research Applied Research Collaboration North West Coast (NIHR ARC NWC). A consortium of pharmaceutical companies (GSK, EISAI, UCB Pharma) funded the National Audit of Seizure Management in Hospitals (NASH) through grants paid to University of Liverpool.

Figures

1
1
Study flow diagram. Date of search 11 August 2020. RCT: randomised controlled trial.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
4
4
Forest plot of comparison: 1 Gabapentin versus placebo, outcome: 1.1 Reduction in seizure frequency 50% or greater.
1.1
1.1. Analysis
Comparison 1: Gabapentin versus placebo, Outcome 1: Reduction in seizure frequency ≥ 50%
1.2
1.2. Analysis
Comparison 1: Gabapentin versus placebo, Outcome 2: Treatment withdrawal
1.3
1.3. Analysis
Comparison 1: Gabapentin versus placebo, Outcome 3: Adverse effects
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Anhut 1994 {published and unpublished data}
    1. Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia 1994;35(4):795-801. [PMID: ] - PubMed
Appleton 1999 {published data only}
    1. Appleton R, Fichtner K, LaMoreaux L, Alexander J, Halsall G, Murray G, et al, and the Gabapentin Paediatric Study Group. Gabapentin as add-on therapy in children with refractory partial seizures: a 12 week, multicentre, double blind placebo controlled study. Epilepsia 1999;40(8):1147-54. [PMID: ] - PubMed
Fisher 2001 {published data only}
    1. Fisher RS, Sachdeo RC, Pellock J, Penovich PE, Magnus L, Bernstein P. Rapid Initiation of gabapentin: a randomised control trial. Neurology 2001;56(6):743-8. [PMID: ] - PubMed
French 2016 {published data only}
    1. French J, Glue P, Friedman D, Almas M, Yardi N, Knapp L, et al. Adjunctive pregabalin vs gabapentin for focal seizures: interpretation of comparative outcomes. Neurology 2016;87(12):1242-9. [PMID: ] - PMC - PubMed
Leach 1997 {published data only}
    1. Leach JP, Girvan J, Paul A, Brodie MJ. Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry 1997;62(4):372-6. [PMID: ] - PMC - PubMed
Lindberger 2000 {published data only}
    1. Lindberger M, Alenius M, Frisen L, Johannessen SI, Larsson S, Malmgren K, et al, on behalf of the GREAT Study Investigators Group. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study. Epilepsia 2000;41(10):1289-95. [PMID: ] - PubMed
Sethi 2002 {published data only}
    1. Sethi A, Chandra D, Puir V, Mallika V. Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine. Neurology India 2002;50(3):359-63. [PMID: ] - PubMed
Sivenius 1991 {published and unpublished data}
    1. Sivenius J, Kalviainen R, Ylinen A, Riekkinen P. Double blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991;32(4):539-42. [PMID: ] - PubMed
Tomovic 1999 {published data only}
    1. Tomovic M, Ilic T, Mihajlovic M, Jovicic A. Gabapentin as adjuvant therapy in the treatment of refractory partial epilepsy. Vojnosanitetski Pregled 1999;56(2):151-6. [PMID: ] - PubMed
UK Gabapentin 1990 {published and unpublished data}
    1. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990;335(8698):1114-7. [PMID: ] - PubMed
US Gabapentin 1993 {published and unpublished data}
    1. US Gabapentin Study Group No 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993;43(11):2292-8. [PMID: ] - PubMed
Yamauchi 2006 {published data only}
    1. Yamauchi T, Kaneko S, Vagi K, Sase S. Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry and Clinical Neurosciences 2006;60(4):507-15. [PMID: ] - PubMed

References to studies excluded from this review

Arya 2013 {published data only}
    1. Arya R, Glauser TA. Pharmacotherapy of focal epilepsy in children: a systematic review of approved agents. CNS Drugs 2013;27(4):273-86. [PMID: ] - PMC - PubMed
Bodalia 2013 {published data only}
    1. Bodalia PN, Grosso AM, Sofat R, Macallister RJ, Smeeth L, Dhillon S, et al. Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trials. British Journal of Clinical Pharmacology 2013;76(5):649-67. [PMID: ] - PMC - PubMed
Btaiche 1995 {published data only}
    1. Btaiche IF, Woster PS. Gabapentin and lamotrigine: novel antiepileptic drugs. American Journal of Health-system Pharmacy 1995;52(1):61-9. [PMID: ] - PubMed
Crawford 1987 {published data only}
    1. Crawford P, Ghadiali E, Lane R, Blumhardt L, Chadwick DW. Gabapentin as an antiepileptic drug in man. Journal of Neurology, Neurosurgery, and Psychiatry 1987;50(6):682-6. [PMID: ] - PMC - PubMed
Jacoby 2015 {published data only}
    1. Jacoby A, Sudell M, Tudur Smith C, Crossley J, Marson AG, Baker GA. Quality-of-life outcomes of initiating treatment with standard and newer antiepileptic drugs in adults with new-onset epilepsy: findings from the SANAD trial. Epilepsia 2015;56(3):460-72. [PMID: ] - PubMed
Korean Gabapentin Study Group 2000 {published data only}
    1. Korean Gabapentin Study Group. Comparative clinical trial of gabapentin and sodium valproate as add-on therapy in refractory partial epilepsies: open randomized multicenter trial. Journal of Korean Epilepsy Society 2000;4(1):19-26.
Nonoda 2014 {published data only}
    1. Nonoda Y, Iwasaki T, Ishii M. The efficacy of gabapentin in children of partial seizures and the blood levels. Brain & Development 2014;36(3):194-202. [PMID: ] - PubMed
Ohtsuka 2014 {published data only}
    1. Ohtsuka Y. New antiepileptic drugs: characteristics and clinical applications. Japanese Journal of Clinical Medicine 2014;72(5):931-8. [PMID: ] - PubMed
Ramsay 1994 {published data only}
    1. Ramsay RE. Clinical efficacy and safety of gabapentin. Neurology 1994;44(6 Suppl 5):S23-30;discussion S31-2. [PMID: ] - PubMed
Schmidt 2001 {published data only}
    1. Schmidt D, Elger CE, Brandl U, Schmitz B, Steinhoff BJ, Bauer G, et al. Recommendations for the treatment of partial epilepsies with gabapentin A – a consensus. Nervenheilkunde 2001;20(10):580-5.
Semah 2014 {published data only}
    1. Semah F, Thomas P, Coulbaut S, Derambure P. Early add-on treatment vs alternative monotherapy in patients with partial epilepsy. Epileptic Disorders 2014;16(2):165-74. [PMID: ] - PubMed

References to studies awaiting assessment

Kwan 2000 {published data only}
    1. Kwan SY, Yiu CH, Su MS. A double blind study of gabapentin in partial seizures. Epilepsia 2000;41(Suppl Florence):69.
Shapiro 2000 {published data only}
    1. Shapiro DY, Nordli D, Glauser TA, Knapp LE, Greiner M, Purcell TJ, et al. Gabapentin as add-on therapy for refractory partial seizures in children 1–36 months of age: a novel, short-term, placebo-controlled trial. Epilepsia 2000;41(Suppl 7):106, Abstract no: 2.065.

Additional references

Barker‐Haliski 2014
    1. Barker-Haliski M, Sills GJ, White HS. What are the arguments for and against rational therapy for epilepsy? Advances in Experimental Medicine and Biology 2014;813:295-308. [PMID: ] - PubMed
British National Formulary
    1. British National Formulary. www.bnf.org/.
Cockerell 1995
    1. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346(8968):140-4. [PMID: ] - PubMed
GRADEpro GDT [Computer program]
    1. McMaster University (developed by Evidence Prime) GRADEpro GDT. Version accessed 2015. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.
Hauser 1993
    1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993;34(3):453-68. [PMID: ] - PubMed
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.
Higgins 2020
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.
Kirkham 2010
    1. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. [PMID: ] - PubMed
Lefebvre 2020
    1. Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M-I, et al. Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, et al (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.
Loscher 2002
    1. Loscher W. Current status and future directions in the pharmacotherapy of epilepsy. Trends in Pharmacological Sciences 2002;23(3):113-8. [PMID: ] - PubMed
McClean 1995
    1. McClean MJ. Gabapentin. Epilepsia 1995;36(Suppl 2):S73-S86. [PMID: ] - PubMed
McCullagh 1989
    1. McCullagh P, Nelder JA. Generalized Linear Models. 2nd edition. London: Chapman and Hall, 1989.
Panebianco 2015
    1. Panebianco M, Rigby A, Weston J, Marson AG. Vagus nerve stimulation for partial seizures. Cochrane Database of Systematic Reviews 2015, Issue 4. Art. No: CD002896. [DOI: 10.1002/14651858.CD002896.pub2] - DOI - PMC - PubMed
Review Manager 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Reynolds 1981
    1. Reynolds EH, Shorvon SD, Galbraith AW, Chadwick D, Dellaportas L, Vydelingum L. Phenytoin monotherapy for epilepsy: a long term prospective study, assisted by serum level monitoring, in previously untreated patients. Epilepsia 1981;22(4):475-88. [PMID: ] - PubMed
Scheffer 2017
    1. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):512-21. [PMID: ] - PMC - PubMed
Schünemann 2013
    1. Schünemann H, Brożek J, Guyatt G, Oxman A, editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html (accessed prior to 18 November 2020).
West 2019
    1. West S, Nolan SJ, Cotton J, Gandhi S, Weston J, Sudan A, et al. Surgery for epilepsy. Cochrane Database of Systematic Reviews 2019, Issue 6. Art. No: CD010541. [DOI: 10.1002/14651858.CD010541.pub3] - DOI - PMC - PubMed

References to other published versions of this review

Al‐Bachari 2013
    1. Al-Bachari S, Pulman J, Hutton JL, Marson AG. Gabapentin add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No: CD001415. [DOI: 10.1002/14651858.CD001415.pub2] - DOI - PubMed
Marson 1999
    1. Marson AG, Kadir ZZ, Hutton JL, Chadwick DW. Gabapentin add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews 1999, Issue 1. Art. No: CD001415. [DOI: 10.1002/14651858.CD001415] - DOI - PubMed
Panebianco 2018
    1. Panebianco M, Al-Bachari S, Weston J, Hutton JL, Marson A. Gabapentin add-on treatment for drug-resistant focal epilepsy. Cochrane Database of Systematic Reviews 2018, Issue 10. Art. No: CD001415. [DOI: 10.1002/14651858.CD001415.pub3] - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources